308 related articles for article (PubMed ID: 26420061)
1. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Chen CI; Masih-Khan E; Jiang H; Rabea A; Cserti-Gazdewich C; Jimenez-Zepeda VH; Chu CM; Kukreti V; Trudel S; Tiedemann R; Tsang R; Reece DE
Br J Haematol; 2013 Aug; 162(4):483-8. PubMed ID: 23772701
[TBL] [Abstract][Full Text] [Related]
3. Emergence of central nervous system myeloma in the era of novel agents.
Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias AL; Vij R; Fiala MA; Caers J; Rasche L; Nooka AK; Lonial S; Vesole DH; Philip S; Gangatharan S; Druzd-Sitek A; Walewski J; Corso A; Cocito F; Vekemans MC; Atilla E; Beksac M; Leleu X; Davila J; Badros A; Aneja E; Abildgaard N; Kastritis E; Fantl D; Schutz N; Pika T; Butrym A; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Usmani SZ; Nahi H; Chim CS; Shustik C; Madry K; Lentzsch S; Swiderska A; Helbig G; Guzicka-Kazimierczak R; Lendvai N; Waage A; Andersen KT; Murakami H; Zweegman S; Castillo JJ
Am J Hematol; 2016 Jun; 91(6):575-80. PubMed ID: 26955792
[TBL] [Abstract][Full Text] [Related]
5. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
6. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Abdallah AO; Atrash S; Shahid Z; Jameel M; Grazziutti M; Apewokin S; Kumar NS; Restrepo A; Waheed S; Van Rhee F; Heuck CJ; Johann D; Barlogie B; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):211-4. PubMed ID: 24373936
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.
Lee D; Kalff A; Low M; Gangatharan S; Ho P; Bajel A; Ritchie D; Grigg A; Spencer A
Br J Haematol; 2013 Aug; 162(3):371-5. PubMed ID: 23718539
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.
Gozzetti A; Cerase A; Lotti F; Rossi D; Palumbo A; Petrucci MT; Patriarca F; Nozzoli C; Cavo M; Offidani M; Floridia M; Berretta S; Vallone R; Musto P; Lauria F; ; Marchini E; Fabbri A; Oliva S; Zamagni E; Sapienza FG; Ballanti S; Mele G; Galli M; Pirrotta MT; Di Raimondo F
Cancer; 2012 Mar; 118(6):1574-84. PubMed ID: 21932386
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
12. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
13. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
15. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Kastritis E; Zervas K; Symeonidis A; Terpos E; Delimbassi S; Anagnostopoulos N; Michali E; Zomas A; Katodritou E; Gika D; Pouli A; Christoulas D; Roussou M; Kartasis Z; Economopoulos T; Dimopoulos MA
Leukemia; 2009 Jun; 23(6):1152-7. PubMed ID: 19225533
[TBL] [Abstract][Full Text] [Related]
16. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
17. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
[TBL] [Abstract][Full Text] [Related]
18. Myelomatous Involvement of the Central Nervous System.
Paludo J; Painuly U; Kumar S; Gonsalves WI; Rajkumar V; Buadi F; Lacy MQ; Dispenzieri A; Kyle RA; Mauermann ML; McCurdy A; Dingli D; Go RS; Hayman SR; Leung N; Lust JA; Lin Y; Gertz MA; Kapoor P
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):644-654. PubMed ID: 27624224
[TBL] [Abstract][Full Text] [Related]
19. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Cheah CY; Bröckelmann PJ; Chihara D; Moskowitz AJ; Engert A; Jerkeman M; El-Galaly TC; Augustson B; Vose J; Bartlett NL; Villa D; Connors JM; Feldman T; Pinnix CC; Milgrom SA; Dabaja B; Oki Y; Fanale MA
Am J Hematol; 2016 Sep; 91(9):894-9. PubMed ID: 27222367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
